Immunological effects of local low-dose immunotherapy in early stage melanoma patients
Phase 2
Completed
- Conditions
- Clinical stage I-II melanomaCancer
- Registration Number
- ISRCTN63321797
- Lead Sponsor
- VU University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Patients with histologically proven primary melanoma, who are eligible for a SLN biopsy.
Exclusion Criteria
1. Treated with chemotherapy or immunotherapy in the last ten years
2. Autoimmune diseases
3. Congenital or acquired immunodeficiency
4. Use of immunosuppressive medications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie GM-CSF and CpG 7909 immunomodulation in melanoma sentinel lymph nodes?
How does pre-operative GM-CSF/CpG 7909 compare to standard adjuvant therapies for stage I-II melanoma?
Which biomarkers correlate with immune response enhancement in ISRCTN63321797 melanoma trial?
What adverse events are associated with GM-CSF and CpG 7909 in early stage melanoma patients?
Are there synergistic combinations of GM-CSF/CpG 7907 with other immune checkpoint modulators for melanoma?